Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Dermatologic 1Breast 1

Conditions

Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Solid Tumours 5Melanoma 5Neurofibromatosis 1 4Lung Neoplasms 4Rectal Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Neurofibroma, Plexiform 2Uveal Melanoma 1Solid Tumors 1Renal Insufficiency 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Cancer 1Locally Advanced or Metastatic Solid Tumors 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Healthy Volunteers Pharmacokinetic Study 1Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Advanced Non Small Cell Lung Cancer 1Advanced Cancer 1Adult Solid Neoplasm 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × AZD 6244 × Clear all
NCT02188264 2025-02-11

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01287130 2019-12-17

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡